Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 27, 2025Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine

Advancing Therapeutic Horizons in Erythrodermic Psoriasis: A Comprehensive Review of Pathophysiology, Biomarkers, and Novel Treatments

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShatrudhan PrajapatiASAjay Pal SinghSYShikha Yadav

Discussion

Loading...

Member takes

Overview

Comprehensive review reveals immunological factors and therapeutic options in erythrodermic psoriasis, highlighting the role of biologics.

Key Points

  • Erythrodermic psoriasis requires individualized management due to its severe clinical implications.
  • Key biomarkers like IL-4 and IL-10 are crucial for understanding disease pathways and treatment response.
  • Biologics targeting immune pathways have transformed treatment outcomes for patients with erythrodermic psoriasis.
  • Gaps in predictive biomarker identification and treatment standardization highlight areas needing further research.

Cite This Study

Prajapati et al. (2025) studied this question.

synapsesocial.com/papers/68d7be66eebfec0fc5237ef4https://doi.org/10.2174/0118756921384260250917174754
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review2025 · 4 citations
  2. 2Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study2026
  3. 3Update on the Etiology and Pathogenesis of Erythrodermic Psoriasis2026
  4. 4Evolving Paradigms in Psoriasis Treatment: Bridging Traditional Therapies with Technological Innovations2025
  5. 5Ayurvedic Management of Severe Erythrodermic Psoriasis: A Case Report2025